Novo Nordisk’s obesity drug Wegovy slashed the risk of serious heart problems by 20% in a large clinical trial. That landmark finding could put more pressure on U.S. insurers to cover the blockbuster medication and similar weight loss treatments. But organizations representing insurers emphasized that the data is still preliminary, and concerns remain about the … Read more
Popular weight-loss drug Wegovy could be made available under more health insurance schemes following the results of a late-stage trial, analysts said Wednesday. Novo Nordisk’s closely watched “SELECT” trial exceeded expectations Tuesday, indicating that Wegovy reduced the risk of major cardiovascular events such as heart attacks or strokes by 20%. “Data like this is going … Read more
Crypto prices should be viewed more like internet stocks than currency, said Brian Brooks, the former U.S. Acting Comptroller of the Currency during the Trump Administration. The biggest misunderstanding around cryptocurrencies is that if they’re “not doing a great job of replacing the U.S. dollar, then crypto is failing in its mission,” Brooks, now the … Read more